<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532519</url>
  </required_header>
  <id_info>
    <org_study_id>horcoop-hmo-ctil</org_study_id>
    <nct_id>NCT00532519</nct_id>
  </id_info>
  <brief_title>Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which&#xD;
      appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin&#xD;
      scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless,&#xD;
      in many cases no underlying physical disease is present. According to the literature, in&#xD;
      fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform&#xD;
      disorders.&#xD;
&#xD;
      We hypothesize that a group of these patients may benefit from antidepressant therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Prurigo Nodularis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram (cipralex)</intervention_name>
    <description>10-20 mg/day, for 12 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  prurigo nodularis&#xD;
&#xD;
          -  age: 18-70 years&#xD;
&#xD;
          -  agreed to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  younger than 18 or older than 70&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  chronic diseases: cancer, neurological disorders, diseases that are known to be&#xD;
             associated with pruritus such as liver cirrhosis, uremia, etc.&#xD;
&#xD;
          -  sensitivity to cipralotam&#xD;
&#xD;
          -  psychosis, bi-polar disorder, substance addiction, use of antidepressant in the&#xD;
             previous year&#xD;
&#xD;
          -  use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>liran horev, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>rena cooper-kazaz, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liran Horev, MD</last_name>
    <phone>OO97226777111</phone>
    <email>LIRAN_CH@BEZEQINT.NET</email>
  </overall_contact>
  <location>
    <facility>
      <name>: Hadassah Medical Organization,</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Arik Tzukert, DMD</last_name>
      <phone>00 972 2 6776095</phone>
      <email>arik@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>00 972 2 6777572</phone>
      <email>: lhadas@hadassah.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>September 19, 2007</last_update_submitted>
  <last_update_submitted_qc>September 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

